HK1043306B - 用於藥物用途的16-苯氧基-脂氧素類似物 - Google Patents

用於藥物用途的16-苯氧基-脂氧素類似物

Info

Publication number
HK1043306B
HK1043306B HK02104450.3A HK02104450A HK1043306B HK 1043306 B HK1043306 B HK 1043306B HK 02104450 A HK02104450 A HK 02104450A HK 1043306 B HK1043306 B HK 1043306B
Authority
HK
Hong Kong
Prior art keywords
phenoxy
medical use
lipoxin analogs
lipoxin
analogs
Prior art date
Application number
HK02104450.3A
Other languages
English (en)
Chinese (zh)
Other versions
HK1043306A1 (en
Inventor
Charles N Serhan
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of HK1043306A1 publication Critical patent/HK1043306A1/xx
Publication of HK1043306B publication Critical patent/HK1043306B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/035—Halogenated hydrocarbons having aliphatic unsaturation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK02104450.3A 1999-03-18 2002-06-14 用於藥物用途的16-苯氧基-脂氧素類似物 HK1043306B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12519499P 1999-03-18 1999-03-18
PCT/US2000/006669 WO2000054761A2 (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Publications (2)

Publication Number Publication Date
HK1043306A1 HK1043306A1 (en) 2002-09-13
HK1043306B true HK1043306B (zh) 2010-09-17

Family

ID=22418604

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104450.3A HK1043306B (zh) 1999-03-18 2002-06-14 用於藥物用途的16-苯氧基-脂氧素類似物

Country Status (10)

Country Link
US (5) US6353026B1 (US20080131398A1-20080605-C00009.png)
EP (2) EP1162976B1 (US20080131398A1-20080605-C00009.png)
JP (1) JP4392473B2 (US20080131398A1-20080605-C00009.png)
AT (1) ATE466582T1 (US20080131398A1-20080605-C00009.png)
AU (1) AU780114B2 (US20080131398A1-20080605-C00009.png)
CA (2) CA2645558C (US20080131398A1-20080605-C00009.png)
DE (1) DE60044335D1 (US20080131398A1-20080605-C00009.png)
ES (1) ES2344138T3 (US20080131398A1-20080605-C00009.png)
HK (1) HK1043306B (US20080131398A1-20080605-C00009.png)
WO (1) WO2000054761A2 (US20080131398A1-20080605-C00009.png)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US6745204B1 (en) * 1999-02-12 2004-06-01 Mount Sinai Hospital System for electronically managing, finding, and/or displaying biomolecular interactions
AU2529500A (en) * 1999-02-12 2000-08-29 Mount Sinai Hospital Corporation System for electronically managing, finding, and/or displaying biomolecular interactions
US6387953B1 (en) * 1999-03-18 2002-05-14 Brigham And Women's Hopsital Inhibition of TNF-(α)-initiated neutrophil response
DK1163204T3 (da) * 1999-03-18 2005-12-19 Brigham & Womens Hospital Lipoxinforbindelser og deres anvendelse
ATE466582T1 (de) * 1999-03-18 2010-05-15 Brigham & Womens Hospital 16-phenoxy-lipoxin analoge zur medizinischen verwendung
EP1586550A1 (en) * 1999-03-18 2005-10-19 The Brigham And Women's Hospital, Inc. Lipoxin compounds and their use
CN1951899B (zh) 2000-02-16 2012-02-01 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
WO2001070664A2 (en) * 2000-03-20 2001-09-27 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
GB0119583D0 (en) * 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
WO2003039533A1 (en) * 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
EP2361622A1 (en) * 2001-12-18 2011-08-31 The Brigham and Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
EP1537067B1 (en) * 2002-08-12 2009-11-18 Brigham And Women's Hospital Resolvins: biotemplates for therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
WO2005105025A1 (en) * 2004-04-14 2005-11-10 Boston University Methods and compositions for preventing or treating periodontal diseases
EP1910547A2 (en) 2005-07-29 2008-04-16 Monsanto Technology, LLC Development of novel germplasm using segregates from transgenic crosses
US8273792B2 (en) * 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
EP1954291A1 (en) * 2005-11-18 2008-08-13 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
WO2007127377A2 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Combinations comprising omega-3 fatty acid compounds for the treatment of cardiovascular disease
CN101528218A (zh) * 2006-07-19 2009-09-09 雷索维克斯药品公司 治疗粘膜炎的组合物和方法
EP2131833A2 (en) * 2006-10-26 2009-12-16 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
UY30755A1 (es) 2006-12-04 2008-07-31 Bayer Schering Pharma Ag Sal de potasio cristalina de analogos de lipoxina a4
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
EP2207543A2 (en) * 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
WO2009051670A2 (en) * 2007-10-12 2009-04-23 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for the treatment of ophthalmic conditions
KR101306199B1 (ko) 2012-01-31 2013-09-09 부산대학교 산학협력단 포스포리파아제 ｄ 억제제를 유효성분으로 포함하는 골다공증 예방 및 치료용 약학적 조성물
US9447678B2 (en) 2012-12-01 2016-09-20 Halliburton Energy Services, Inc. Protection of electronic devices used with perforating guns

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
ES2313715T3 (es) * 1993-06-15 2009-03-01 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina con semivida prolongada.
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US5750354A (en) 1994-03-11 1998-05-12 Brigham And Women's Hospital Lipoxin transport system and uses therefor
US6387953B1 (en) * 1999-03-18 2002-05-14 Brigham And Women's Hopsital Inhibition of TNF-(α)-initiated neutrophil response
ATE466582T1 (de) * 1999-03-18 2010-05-15 Brigham & Womens Hospital 16-phenoxy-lipoxin analoge zur medizinischen verwendung
DK1163204T3 (da) * 1999-03-18 2005-12-19 Brigham & Womens Hospital Lipoxinforbindelser og deres anvendelse

Also Published As

Publication number Publication date
CA2645558A1 (en) 2000-09-21
AU3745100A (en) 2000-10-04
WO2000054761A9 (en) 2001-10-25
US6864288B2 (en) 2005-03-08
WO2000054761A3 (en) 2001-03-29
JP2002539156A (ja) 2002-11-19
JP4392473B2 (ja) 2010-01-06
US20020107289A1 (en) 2002-08-08
ES2344138T3 (es) 2010-08-19
US20020120013A1 (en) 2002-08-29
AU780114B2 (en) 2005-03-03
US6927238B2 (en) 2005-08-09
HK1043306A1 (en) 2002-09-13
US20080064751A1 (en) 2008-03-13
CA2645558C (en) 2012-05-15
US6353026B1 (en) 2002-03-05
CA2365240C (en) 2009-01-20
EP1162976A2 (en) 2001-12-19
CA2365240A1 (en) 2000-09-21
EP1162976B1 (en) 2010-05-05
DE60044335D1 (de) 2010-06-17
WO2000054761A2 (en) 2000-09-21
EP2236140A1 (en) 2010-10-06
US20050187294A1 (en) 2005-08-25
ATE466582T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
HK1043306A1 (en) 16-phenoxy-lipoxin analogs for medical use
NZ328898A (en) Sustained release formulation containing collagen and glycosaminoglycan additives
SG148834A1 (en) Compounds for the modulation of ppary activity
AP1697A (en) Azabicycloalkanes as CCR5 modulators.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
ATE220896T1 (de) Hydrogelformulierung mit gesteuerter freisetzung
PT1379246E (pt) Análogos de nociceptina
AP2001002187A0 (en) Piperidines as CCR5 modulators.
GR3033067T3 (en) Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis
NZ509207A (en) Thiobenzimidazole derivative compounds, and usage as chymase activity inhibitors
PT1223980E (pt) Utilizacao de inibidores de csf-1
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
IL147688A0 (en) Synergistic combination
IN2005KO00312A (US20080131398A1-20080605-C00009.png)
MY124786A (en) Bis-arylsulfones
AU3611299A (en) Use of metalloprotinease inhibitors for inducing and/or stimulating growth of hair or hairs and/or for slowing down their loss
GB9804886D0 (en) Therapeutic combination
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
EP1079735A4 (en) REMOTE COUPLING LASER SYSTEM FOR MEDICAL TREATMENT DEVICE
ZA200107425B (en) Method for the treatment of incontinence.
DK0845007T3 (da) Farmaceutisk præparat indeholdende interferon-gamma hæmmere
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
EP1082967A4 (en) PREVENTIVE / TREATMENT PREPARATIONS FOR AUTOIMMUNE DEMYELINIZING DISEASES
PT795008E (pt) Linhas de celulas de condrocitos hipertroficos humanos

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM BRIGHAM AND WOMEN S HOSPITAL TO THE BRIGHAM AND WOMEN S HOSPITAL, INC

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140314